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ABSTRACT
Objectives: The increasing prevalence of overweight
and obesity worldwide continues to compromise
population health and creates a wider societal cost in
terms of productivity loss and premature mortality.
Despite extensive international literature on the cost of
overweight and obesity, findings are inconsistent
between Europe and the USA, and particularly within
Europe. Studies vary on issues of focus, specific costs
and methods. This study aims to estimate the
healthcare and productivity costs of overweight and
obesity for the island of Ireland in 2009, using both
top-down and bottom-up approaches.
Methods: Costs were estimated across four
categories: healthcare utilisation, drug costs, work
absenteeism and premature mortality. Healthcare costs
were estimated using Population Attributable Fractions
(PAFs). PAFs were applied to national cost data for
hospital care and drug prescribing. PAFs were also
applied to social welfare and national mortality data to
estimate productivity costs due to absenteeism and
premature mortality.
Results: The healthcare costs of overweight and
obesity in 2009 were estimated at €437 million for the
Republic of Ireland (ROI) and €127.41 million for NI.
Productivity loss due to overweight and obesity was up
to €865 million for ROI and €362 million for NI. The
main drivers of healthcare costs are cardiovascular
disease, type II diabetes, colon cancer, stroke and
gallbladder disease. In terms of absenteeism, low back
pain is the main driver in both jurisdictions, and for
productivity loss due to premature mortality the
primary driver of cost is coronary heart disease.
Conclusions: The costs are substantial, and urgent
public health action is required in Ireland to address
the problem of increasing prevalence of overweight and
obesity, which if left unchecked will lead to
unsustainable cost escalation within the health service
and unacceptable societal costs.
INTRODUCTION
The increasing prevalence of overweight and
obesity in recent decades poses signiﬁcant
threats to the health and well-being of popula-
tions and represents a major challenge for
health services. In a systematic analysis of data
from 199 countries, it was estimated that 1.46
billion adults worldwide were overweight in
2008, of which 502 million were obese.1
Trends over the past 20 years in the USA
suggest that the number of people in the
highest body mass index (BMI) group is
increasing faster than any other group. From
2000 to 2005, the estimated prevalence of
obesity in the USA based on self-reported
height and weight increased by 24%.
However, the prevalence of morbid obesity
(BMI >40 kg/m2) increased by 50% and the
prevalence of a BMI of over 50 kg/m2
increased by 75%, during this period in
the USA.2
In the Republic of Ireland (ROI), the 2007
Survey of Lifestyle, Attitudes and Nutrition in
Ireland (SLÁN) provides estimates of BMI
based on self-reported height and weight3
(Ireland refers to the ROI, while Northern
Ireland (NI) refers to the Northern part of
Ireland which is part of the UK, and the Island
of Ireland refers to the whole) More than
Strengths and limitations of this study
▪ This study provides a significant contribution to
the existing evidence base as it is the first exten-
sive investigation of the cost associated with
overweight and obesity on the island of Ireland,
enabling comparisons to be made across both
jurisdictions.
▪ The healthcare and lost productivity costs of
overweight and obesity are examined in the
study which further enhances the robust scope
of the research.
▪ Omitted from the analysis were several aspects
of service where additional demand is likely to
emerge as a result of overweight and obesity,
that is, long-term care, social care, personal
social services and dietician services. Costs that
fall on the individual rather than the health
service were also omitted. Owing to the absence
of adequate reliable data on which to base esti-
mates, the derived summary cost estimates are
likely to be conservative.
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one-third of respondents (36%) were classiﬁed as over-
weight (43% of men and 28% of women) and 14% as
obese (16% of men and 13% of women), while a mea-
sured subset showed the prevalence to be 39% overweight
and 25% obese. More recent data on the prevalence of
overweight and obesity in adults aged 50+ years in the ROI
using measured BMI4 reported a prevalence of overweight
of 47% in men and 40% in women, and a prevalence of
obesity of 37% in men and 31% in women aged 50+ years.
Results from the Health Survey for Northern Ireland 2011
have also revealed similar prevalence rates for NI with 36%
of adults reported as overweight and 23% as obese.5
Overweight and obesity are implicated in the aetiology
of a large number of medical conditions. They are asso-
ciated with signiﬁcantly increased risk of type II diabetes,
cardiovascular disease, several cancers and a number of
additional chronic conditions.6 The WHO has described
chronic disease (mainly cardiovascular disease, diabetes,
asthma and chronic obstructive pulmonary disease) as
the ‘leading threat to human health and development’.7
The WHO’s project, the Global Burden of Disease, has esti-
mated that chronic diseases are the largest contributor
to mortality and disability in high-income countries and
that by 2030, 89% of disability adjusted life years
(DALYs) will be attributed to chronic conditions.7
Estimates of the economic burden of illness can
provide useful information for priority setting, policy
development, assessment of health technologies and
investment in prevention and clinical services. Health
systems worldwide are struggling to meet the challenge
of increasing demand for healthcare and of increasing
expense with diminishing resources. Cost of illness
studies for major health risks such as overweight and
obesity therefore have the potential to frame core policy
issues in language that is tangible and accessible to pol-
icymakers. International cost of illness estimates of over-
weight and obesity have demonstrated substantial costs.
The published estimates for the healthcare cost of
increased BMI in the UK range from approximately £3.2
Billion to £4.2 Billion.8 9 These ﬁgures represent around
5% of the total healthcare spending in the UK for the
years concerned. In similar studies, it has been estimated
that in the USA between 4.8%10 and over 9%11 of total
healthcare spending is due to overweight and
obesity-related illness.
Few estimates exist for the costs associated with over-
weight and obesity for Ireland. The costs in terms of hos-
pital inpatient stays only were estimated at €4.4 million
in 1997, rising to €13.3 million in 2004.12 The National
Taskforce on Obesity estimated that the direct health-
care cost of obesity in Ireland in 2002 was €70 million,
and the indirect cost was €0.37 billion, giving a total cost
of €0.4 billion.13 However, this estimate was based mainly
on data from the UK, which were adjusted for Ireland,
with limited data from the Irish Hospital Inpatient
Enquiry (HIPE) database included. In NI, there is a
relative paucity of cost data to help inform policy
responses. Given Ireland’s health service and population
characteristics, it is difﬁcult to reliably estimate the cost
of illness by extrapolation from published international
data. Furthermore, much of the previous literature
focused only on healthcare costs of obesity, productivity
costs being largely ignored. The aim of this paper is to
provide a comprehensive estimate of the healthcare and
productivity costs of overweight and obesity in the ROI
and NI in 2009. Decomposing differences in cost on the
two parts of the island would provide an interesting and
useful exercise in, for example, investigating the impact
on healthcare costs that differences in access to public
services might have. As this was not the focus of this
paper and mindful of constraints on space, we have
chosen not to provide such an analysis here.
MATERIALS AND METHODS
We adopted a societal perspective (ie, that includes
healthcare costs and lost productivity) in estimating the
economic cost of overweight and obesity. We focused on
estimating costs across four key categories: healthcare
utilisation, drug costs, work absenteeism and premature
mortality. We used population attributable fractions
(PAFs) calculated by age and gender and applied to
national cost data analysis of hospital inpatient, day cases
and also prescribing data in the ROI and NI. Similarly,
PAFs were applied to social welfare (SW) data and to
national mortality data to calculate the productivity costs
due to absenteeism and premature mortality. There
were no data availability for which general practitioner
(GP) costs could be analysed from a top-down approach,
so we based our estimates on work previously carried out
by this group, using a bottom-up approach.14 15 Table 1
outlines the data sources used in this study.
Population attributable fractions
In this study, PAFs were calculated using the following
formula which accounts for multiple levels of exposure:21
PAF ¼ PF1{RR1  1}þ PF2{RR2  1}
1þ PF1{RR1  1}þ PF2{RR2  1}
where PF1 is the fraction of the population in exposure
level 1 (eg, overweight), RR1 is the relative risk of disease
for exposure level 1, PF2 is the fraction of the population
in exposure level 2 (eg, obese) and RR2 is the relative risk
of disease for exposure level 2. All the PAFs used in these
calculations were based on measured BMI prevalence
rates, calculated from the measured subset of the SLÁN
survey for the ROI and the 2010/2011 Health Survey
Northern Ireland, and using RRs from the international
literature as outlined in table 1. PAFs were calculated by
the 5-year age group for ROI and the 10-year age groups
for NI, separately for males and females for each condi-
tion including low back pain, osteoarthritis, coronary
artery disease and stroke.
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Healthcare utilisation
For hospital inpatient and day cases, PAFs of the speciﬁc
overweight and obesity-related conditions were applied
to the Hospital Inpatient Enquiry (HIPE) database for
the ROI, and Hospital Inpatient Statistics (HIS) data for
NI. HIPE in the ROI and HIS in NI are the primary
sources of national data on discharges from acute hospi-
tals and collect demographic, clinical and administrative
data on discharges from and deaths in acute public hos-
pitals nationally.i In both data sets, the diagnosis related
groups (DRGs) are the cost groups for patient dis-
charges, and for each condition they were summed by
5-year age group and gender. The PAFs for overweight
and obesity-related conditions were applied to the
summed DRGs to give the proportion of costs that could
be attributed to overweight and obesity. The
International Classiﬁcation of Diseases (ICD) codes
included in these analyses are outlined in table 2.
Our estimates of GP and outpatient costs for the ROI
are based on published literature. Doherty et al15 used data
from SLÁN 2007 to estimate the impact of overweight and
obesity on GP service use and outpatient services. They
provide a detailed description of the model used and the
regression analyses performed. Brieﬂy, they estimated the
difference in the probability of individuals using their GP
associated with elevated BMI, controlling for covariates
and, based on this, estimated the impact of overweight
and obesity on service use. This was then combined with
the cost of the service, to estimate the additional cost asso-
ciated with overweight and obesity. Estimates of average
visit frequency for the adult population were taken from
the Quarterly National Household Survey (QNHS) Q3
200722 and costs were taken from published sources in the
literature; more details of these are given in Doherty et al15
In the base case analysis, the cost of a GP consultation was
estimated at €50, of an inpatient episode at €503023 and of
an outpatient visit at €139 (personal communication:
Mark Connors Casemix unit, HSE). They calculated the
cost of GP use associated with overweight and obesity as
being €22 900 000.
For NI, we used data from the grey literature that used
similar methodology for healthcare costs associated with
GP use in NI.14 In that study, data from the 2010/2011
Health Survey Northern Ireland, which is similar to
SLÁN in terms of the issues covered and is based on a
Table 2 Conditions and codes analysed for hospital
inpatient and day-case analysis
Condition ICD Codes
Cancer of the colon C18, C19, C20
Cancer of the oesophagus C15
Cancer of the gallbladder C23
Cancer of the pancreas C25
Cancer of the breast C50
Cancer of the kidney C64
Type 2 diabetes E11, E13, E14
Cancer of the endometrium C54, C55
Obesity E660, E662, E668, E669
Hypertension I10, I11, I12, I13
Stroke G45, I61, I629, I63, I64, I69
Ischaemic heart disease I20, I21, I22, I23, I24, I25,
I46, I50, I70, I71, I72, I74
Gallbladder disease K80, K81
Pulmonary embolism I26
Low back pain M54.3, M54.4, M54.5
Asthma J45, J46
Table 1 Data sources used in this study
Categories Data Source
Healthcare utilisation Population prevalence of
overweight and obesity
SLÁN3
TILDA Wave 1, 20104
Health Survey for Northern Ireland 20115
GP costs Doherty et al,15 Dee, A14
Hospital inpatient and
day-case costs
HIPE
HIS
Relative risks (RRs) Guh et al6
Parkin and Boyd16
Bhole et al17
Pomp et al18
Drug costs Drug costs PCRS
Work absenteeism Average wages Central Statistics Office (CSO)19 20
Work absent days Department of Social Protection illness benefit data for 2009
Department of Social Development (Northern Ireland)
Premature mortality Mortality CSO (Central Statistics Office) mortality data for 2007 to 2009
Northern Ireland Statistics and Research Agency (NIRSA)
GP, general practitioner; HIPE, Hospital Inpatient Enquiry; HIS, Hospital Inpatient Statistics; PCRS, Primary Care Reimbursement Service;
SLAN, Survey of Lifestyle, Attitudes and Nutrition.
iHIPE data was analysed using the Health Atlas. Health Atlas Ireland is
an open source application which enables web-based mapping of
national health-related data.
Dee A, et al. BMJ Open 2015;5:e006189. doi:10.1136/bmjopen-2014-006189 3
Open Access
group.bmj.com on October 26, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
representative sample of households, were used.
The unit cost for a GP visit of £36 was taken from stand-
ard sources assuming all visits were to the GP surgery
within ofﬁce hours and lasted on average just over
11 min.24 Adjustment was made using purchasing power
parity (PPP) for 2009 to express UK ﬁgures into their
Irish equivalent for comparison purposes with the ROI.
The cost with respect to increased BMI in the case of
GP services was €7 411 564.
Drug costs
Drug cost data for the ROI were obtained from the
Primary Care Reimbursement Service (PCRS) and from
the Business Services Organisation (BSO) for NI, for the
year 2009. The PCRS reimburses community drugs dis-
pensed for those with medical cards (dependent on
means test), with long-term chronic illnesses (dependent
on diagnosis) and those on high-tech drugs, which three
schemes together cover over 50% of the population’s
drug spend. They also reimburse drug payments in
excess of €142 to private patients. The BSO manages
prescribing data on behalf of the health service in NI,
where all citizens have equal cover. The PAFs calculated
were applied to the drug expenditure on drug categor-
ies of relevance including drugs used in the treatment
of type II diabetes, cardiovascular conditions, aspirin
and non-steroidal anti-inﬂammatory agents (reﬂecting
treatments for osteoarthritis). Drug expenditure
included a dispensing fee plus VAT where relevant.
Work absenteeism
Work absenteeism was calculated using social welfare
(SW) data in both jurisdictions. However, the availability
and quality of the available data were variable. In ROI,
the Department of Social Protection runs three SW
schemes which apply to individuals who are unable to
work due to illness. One of these deals mainly with dis-
abilities from birth, and was not relevant to the cost of
obesity. The other two deal with short-term illnesses
from work (the illness beneﬁt scheme (IBS)) and longer
term illness causing inability to work on a long-term
basis (Invalidity Pension). Both of these schemes have
data on work absences that could be related to over-
weight and obesity, but only data from one scheme
(IBS) was available in electronic format. Therefore, we
limited our analysis to this scheme.
Claims were assessed to determine if the principal
medical condition linked to each claim was likely to be
associated with overweight and obesity. The age group
and gender-speciﬁc PAFs were applied to the duration
of illness for each condition, and a productivity loss
value was calculated by costing the length of the claim
by gender and age group-speciﬁc mean total annual
earnings for 2009. The IBS data set not only contains
short-term claims but also many claims spanning the
entire year, which were often found to be initiated long
prior to 2009 (historical claims). These historical claims
were found to have a large effect on the estimated
productivity loss, and were therefore eliminated follow-
ing the primary analysis, giving a truncated data set on
which subsequent analyses were performed. Claims are
not paid until after day 3 of sickness absence in about
90% of cases. Accordingly, 2.7 days (3 days×90%) were
added to each claim. By applying PAFs for the relevant
conditions, estimates of duration of illness were obtained
and were taken as a proxy for lost productivity.
Associated costs were estimated by applying average
gross national wages for men and women to illness dur-
ation attributable to obesity and overweight. For NI, the
number of individuals in receipt of a range of beneﬁts
was obtained from the Analytical Services Unit of the
Department of Social Development (NI) for 2009 by
ICD-10 code. Owing to the available data, it was not pos-
sible to estimate total duration of time off work (as was
performed for the ROI). Therefore, the total amount of
beneﬁt payments made for overweight and
obesity-related conditions was calculated. Using this
information and data on weekly payment rates, the dur-
ation of absent days was calculated from which a prod-
uctivity estimate could be made. It was not possible to
eliminate long-term claims from this data set.
A PAF approach was used to estimate the productivity
loss costs associated with beneﬁts paid to individuals
unable to work due to obesity-related illnesses. The human
capital approach counts any hour not worked as an hour
lost and takes the perspective of the patient. The friction
cost approach takes the employer’s perspective and counts
only hours not worked up while the employee is being
replaced. We estimated both for each jurisdiction. The use
of average earnings to estimate lost productivity is open to
question. Those who are overweight or obese may experi-
ence an earnings penalty related to unobserved character-
istics and/or discrimination in the workplace. Rather than
speculate as to the magnitude of such effects (and their dif-
ferences between jurisdictions), we have used the average
wage ﬁgure but caution as to the interpretation of results.
Premature mortality
Mortality data were obtained from the Irish Central
Statistics Ofﬁce (CSO) for the ROI and the Registrar
General reports for NI covering a 3-year period from
2008 to 2010 inclusive. Deaths for the named conditions
were weighted using years of potential life lost (YPLL)
up to age 75, and also for all ages. Costs were based on
the average income at the age of death, by age and sex,
excluding deaths occurring in those under age 18.
Thirty per cent of the pre-retirement income, reﬂecting
an approximation of the state pension, was used for
people in the 65+ age group. The estimated income at
the time of death was used as the income and a discount
rate of 4% was applied. All analyses were performed
using R. Deaths were manually linked to the ICD-Code
10, described in table 2, which indicated the cause of
death in the individual death records obtained from the
CSO. For each death record, the relevant overweight
and obesity prevalence, and the life expectancy from the
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most recent Life Tables, were linked by age and sex to
the record. The relevant RRs and their upper and lower
CIs were linked by cause of death and sex.
Bottom-up estimates were based on regression analyses
in which a range of health and sociodemographic cov-
ariates featured in the estimated functions. The resultant
cost estimates are based on conditional probabilities of
adiposity and in consequence are to be interpreted as
incremental costs of adiposity. Similarly, in respect of the
top-down estimates of cost, PAFs are based on relative
and not absolute risks of morbidity conditional on adi-
posity and can again be interpreted as incremental costs
of adiposity. The two approaches are different, a fact we
return to in our limitations section.
The issue regarding the use of average earnings not-
withstanding valuing premature death in terms of lost
productivity ignores the broader value to society beyond
production that individuals make as members of families
and social networks. While alternate approaches—for
example using the value of a statistical life—may incorp-
orate such elements, their precision is open to question.
Moreover, as we have not sought to include monetary
values associated with the disutility of obesity-related
morbidity (pain, suffering and anxiety), an attempt to
include them here could appear inconsistent.
RESULTS
Table 3 gives the individual results for each part of the
analysis. The main drivers of healthcare costs due to
drugs and hospital inpatient and day-case care are car-
diovascular disease, type II diabetes, colon cancer, stroke
and gallbladder disease. In terms of absenteeism, low
back pain is the main driver of productivity costs and for
premature mortality the primary driver of productivity
costs is coronary heart disease.
Healthcare utilisation
Hospital inpatient and day-case costs estimated using
PAFs are presented in table 4. Costs for NI are presented
in PPP 2009 Irish Euro for ease of comparison.
Sensitivity analysis was performed using the upper and
lower bound PAFs, which were calculated using the CIs
range for the associated relative risks.6 This gave a range
of €125 686 873 to €216 025 571.
For NI, the PAFs used were calculated using
NI-speciﬁc prevalence data for overweight and obesity.
The total hospital inpatient and day-case cost attribut-
able to overweight and obesity was €42 920 806 (with a
range of €35 204 704—€54 942 260).
Drug costs
The cost of prescribed drugs in the ROI attributable to
overweight and obesity is €234 441 904, which includes all
dispensing and associated costs. This estimation is based
on the PAF approach which was calculated by applying
the overweight and obesity PAFs to the total cost of the
drugs. Cardiovascular (CVD) drugs were found to be a
major contributor to drug costs with CVD costs calculated
at €142 761 929. Diabetes diagnostic kit costs were
estimated to be €30 638 061 and were followed by type 2
diabetes mellitus (€17 620 890), non-steroidal anti-
inﬂammatory drugs (NSAIDs; €13 884 944), aspirin (€11
220 201), antiobesity (€8 418 288), glucosamine (€5 276
736) and topical NSAID costs (€4 620 854).
The cost of prescribed drugs in NI attributable to over-
weight and obesity is €77 074 272. This ﬁgure was esti-
mated using a similar PAF method used for the ROI
whereby prescribing data from the BSO was combined
with PAFs to estimate total costs. Cardiovascular (CVD)
drugs were reported as a substantial source of prescribed
drug cost (€38 916 053), followed by diabetes (€22 233
463) and diagnostic kits (€6 676 919).
Table 3 Breakdown of healthcare and productivity costs
Republic of Ireland Range € Cost €
Healthcare costs A. GP costs (Doherty et al) 15 700 000–30 000 000 22 900 000
B. Inpatient/day case 89 589 111–179 178 223 172 849 916
C. Outpatient (Doherty et al) 0–14 855 791 6 890 000
D. Drugs 156 294 603–312 589 205 234 441 904
Productivity costs E. Absenteeism Human capital approach 104 106 280–164 115 974 135 977 068
F. Absenteeism Friction cost approach 54 904 907–87 400 050 72 133 090
G. Premature mortality 493 000 000–684 000 000 592 991 594
Total A+B+C+D+E+G 85 868 999 4–1 384 739 193 €1 166 050 482
Northern Ireland Range PPP € 2009 Cost PPP 2009 €
Healthcare costs H. GP (Doherty et al) 0–15 210 484 7 411 564
I. Inpatient/day case 28 613 870–57 227 740 42 920 805
J. Drugs 51 382 848–102 765 696 77 074 272
Productivity costs K. Absenteeism Human capital approach 215 000 000–256 000 000 235 500 000
L. Absenteeism Friction cost approach 74 400 000–8 860 000 81 500 000
M. Premature mortality 107 022 854–186 486 711 147 417 113
Total H+I+J+K+L 402 019 572–617 690 631 €510 323 754
GP, general practitioner.
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Lost productivity
For the ROI, overweight and obesity-related conditions
in 2009 resulted in 266 553 claims to the IBS, made by
202 246 claimants, of whom 57.4% were female and
42.6% male. The summed 2009 duration of illness/work
absence was 34 322 years. PAFs were applied to the rele-
vant conditions to estimate absolute years lost and the
percentage of the 2009 illness duration total. The total
duration of illness due to overweight and obesity for
2009 was estimated at 3117 years. Overweight and
obesity-related illness beneﬁt claims accounted for
9.08% of the summed 2009 duration of all illnesses. For
the human capital approach, these durations were trans-
formed through the application of age and gender
appropriate 2009 earnings into the yearly productivity
loss cost estimates. The estimated annual productivity
loss costs in the ROI due to absenteeism related to over-
weight and obesity was €135 977 068 for 2009.
Productivity losses for the ROI were also estimated using
the friction cost approach. In this approach, claims
longer than 90 days were capped, giving a friction cost
estimate for productivity loss due to overweight and
obesity-related conditions of €72 133 090 for 2009.
The estimated annual productivity loss costs in NI due
to absenteeism related to overweight and obesity is €215
million using the Human Capital Approach and €74.4
million using the Friction Cost Approach.
Premature mortality
In the ROI, the estimated cost of life years lost due
to obesity and overweight was calculated at a total of
€853 070 261, of which €276 496 546 accounted for
female deaths and €576 573 715 for male deaths. These
ﬁgures are presented as income weighted years of
potential life lost for all ages based on life expectancy.
The total ﬁgure represents 9% of the total income-
weighted years of life lost from 2007 to 2009 in the ROI.
The estimated cost of life years lost to age 75 due to
overweight and obesity was €684 747 065, of which
€190 542 208 accounted for female deaths and €494 204
857 accounted for male deaths. The total ﬁgure repre-
sents 8.3% of the total income-weighted potential years
of life lost from 2007 to 2009 in the ROI. The basic ana-
lysis used undiscounted years of life and weights these
years of life using undiscounted income. As part of the
sensitivity analysis, the effect of using different discount
rates, 2%, 4%, 6%, 8% and 10%, was investigated. As
expected, both the absolute number of years of life lost
and the corresponding costs fall sharply. The ﬁgures are
shown in table 5 below.
Using the Irish Department of Finance recommended
discount rate of 4%, the total annual productivity loss
cost estimated for the ROI, using measured BMI for
prevalence rates, and only counting those who died
aged 18–75 was €592 991 594.
For NI, the annual cost of premature mortality attrib-
utable to overweight and obesity was €147 417 113. By
applying the upper and lower bound range relating to
the range of RRs used in the analysis, the range calcu-
lated for costs is €107 022 854 to €186 486 711 million.
DISCUSSION
This is the ﬁrst comprehensive study of the cost of over-
weight and obesity on the island of Ireland, which allows
comparisons to be made across both jurisdictions. The
study focused on estimating both the healthcare and
productivity costs of overweight and obesity, and
although it takes a primarily top-down approach, it also
draws on bottom-up approaches. The cost of overweight
and obesity in the ROI was €1.16 billion, and for NI it
was €510 million. NI has a population of about one-third
of the ROI. Their health system is part of the UK’s
National Health Service (NHS) in which care is deliv-
ered free at the point of use, while in the ROI a mixed
system in which a greater role is afforded private
medical insurance operates. If the systems were equiva-
lent, that is, if healthcare was also free at the point of
use in the ROI, one would expect a rise in demand, with
increased costs, although the fact that healthcare is
Table 4 Overweight and obesity attributable to hospital
inpatient and day-case costs for the Republic of Ireland
and Northern Ireland in 2009
Condition
Republic of
Ireland
Northern
Ireland
Cancer of the colon 18 886 971 4 596 358
Cancer of the oesophagus 1 276 788 358 790
Cancer of the gallbladder 117 074 21 093
Cancer of the pancreas 2 875 482 595 706
Cancer of the breast 1 849 663 437 283
Cancer of the kidney 3 930 254 783 888
Type 2 diabetes 28 602 917 2 497 957
Cancer of the endometrium 2 735 495 840 822
Obesity 411 206 24 594
Hypertension 2 539 053 513 366
Stroke 13 284 656 4 105 929
Ischaemic heart disease 72 148 580 20 664 359
Gallbladder disease 12 493 037 4 864 114
Pulmonary embolism 5 193 900 1 264 792
Low back pain 5 293 816 993 325
Asthma 1 211 024 358 429
Total €172 849 916 €42 920 806
Table 5 Sensitivity analysis around discount rates for
premature mortality, both jurisdictions
Northern Ireland Republic of Ireland
Discount rate Age to 75 Age to 75
0.00% €210 763 565.53 €8 208 337 242
2.00% €173 995 104.01 €7 487 852 062
4.00% €147 417 113.39 €6 878 312 466
6.00% €127 567 162.23 €6 358 103 699
8.00% €112 326 333.97 €5 910 531 821
10.00% €100 345 294.30 €5 522 568 832
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relatively price inelastic means that the increase in cost
would be disproportionately less than the rise in
demand. While the different systems might in part
explain some of the differences in cost across the two
jurisdictions—serving to stiﬂe demand for services rela-
tive to that in NI and thereby deﬂate the cost estimation
of the apparent differences—it may also relate to the
use of PPP. PPP provides for the conversion of one cur-
rency to another based on the purchasing power of that
currency domestically. As many of the services valued
here are delivered free at the point of use, conversions
based on speciﬁc comparisons, for example, of a GP
consultation, were not possible. The use of general PPPs
may in consequence not be ideal. If the exchange rate
which was current at the time of the study was used, the
cost for NI is reduced to €416 million.
While the results between the two jurisdictions were
broadly along expected lines for healthcare costs, with
respect to productivity costs the differences were some-
what greater than expected. This was mainly due to the
amount and quality of data made available for the study
of absenteeism. In the ROI, electronic data were only
available for one of two relevant schemes, and so a pro-
portion of the estimated costs was probably excluded.
The data that were available were very detailed, and
allowed for the number of sick days associated with over-
weight and obesity to be estimated with a reasonable
degree of precision. Data for NI were at a much higher
level, and the number of days had to be estimated.
However, data for all relevant schemes were available.
The crudeness of the estimates, however, meant that the
estimates were much less likely to be precise. Therefore,
the ﬁgure for absenteeism for the ROI can be consid-
ered an underestimate, and for NI, most likely a slight
overestimate.
In the ROI, 38% of the total costs were healthcare
costs, amounting to 2.7% of the total healthcare costs
for that year. For NI, healthcare costs were 25% of the
total and 2.8% of the total healthcare costs for 2009.
These results are within the range commonly found in
other European countries,25 although healthcare costs
in the USA tend to be higher, up to 9% of healthcare
spend.11
There are a number of limitations associated with our
analyses. First, omitted from the analysis were several
aspects of service where additional demand is likely to
emerge as a result of needs related to obesity and over-
weight. Such services include long-term care, social care,
personal social services and also dietician services. Also
omitted from the analysis are costs that fall on the indi-
vidual rather than the health service. The latter could
include over-the-counter medicines purchased by the
individual or costs related to the consumption of GP or
hospital services, such as travel, and the copayment
made for drugs by private patients. Also excluded are
the costs of lost production in the self-employed, which
are private rather than societal costs. In each case, the
rationale for the omission of the service resulted from
the absence of adequate reliable data on which to base
estimates. Second, repeated cross-sectional surveys show
us that the population BMI distribution is ‘shifting to
the right,’ but the duration of obesity—the period that
obese people are living with obesity—is probably also
increasing and the cumulative risks of adverse health
events may actually be higher than those we have used
in our analyses (and the costs).26 27 The duration of
obesity, however, is not captured in these cross-sectional
surveys. Third, studies have shown that risk measures of
central adiposity may better predict aspects of morbidity
than BMI.28–30 While using alternate measures may have
helped increase the precision of some of our estimates,
BMI was the only measure of adiposity available to us.
Fourth, for productivity losses due to premature mortal-
ity, the cost estimates reﬂect the wage rates in the ROI.
There is considerable uncertainty in these estimates,
reﬂecting the imprecision in estimates of population
attributable fractions and the assumptions, approxima-
tions and simpliﬁcations inherent in this approach to
estimating productivity losses.
Lastly, with respect to those elements where cost esti-
mates were provided a number of simplifying assump-
tions were employed any of which are open to debate.
For example, data constraints obliged the use of differ-
ent methods—bottom-up and top-down—that are not
directly comparable. In the top-down approach, simplify-
ing assumptions were employed in respect, for example,
of average earnings at the time of death, of the value of
lost productivity among the retired, of the duration of
absenteeism in NI, of the interval over which friction
costs were calculated of discount rates used, etc. The use
of lost output when valuing premature death as
opposed, for example, to the value of a statistical life is
similarly open to question. Similarly, in the bottom-up
approach, alternative regression models and survey data
may have resulted in alternative estimates of costs. In
respect of both unobserved characteristics correlated
with adiposity—for example, preferences for health or
attitudes to risk—we acknowledge that we have not been
able to take these into account in this study, and that the
bias from such factors may well lead to an overestimate
of the costs of obesity. While the precision of our esti-
mates should in consequence be treated with some
caution in the spirit of lighting a candle rather than
simply cursing the dark, however, we contend that these
estimates at a minimum help spark a debate in respect
of costs and hopefully help to provoke a policy response.
The limitations notwithstanding, the paper provides
the ﬁrst comprehensive examination of the cost asso-
ciated with obesity and overweight on the island of
Ireland. On balance, the summary cost estimates are
probably conservative, that is, likely to underestimate the
true costs for the reasons detailed above. It quantiﬁes
the not insubstantial costs associated with overweight
and obesity currently in both parts of Ireland. The
upward trend in the prevalence of childhood and adult
obesity indicates that these costs unchecked will increase
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over time. Given the drive in both jurisdictions to
contain healthcare spending and increase productivity, it
seems unlikely that current trends will be sustainable.
Given this, evidence based prevention programmes must
be set in place at all levels of society to tackle this in a
coordinated and sustained fashion.
Lastly, this study was constrained by a lack of suitable
longitudinal or cross-sectional data to allow for a reliable
bottom-up estimate of costs. The top-down approach
using PAFs may have resulted in some overestimation, as
these costs are average costs, and also such calculations
cannot rule out double counting of cases, where mul-
tiple comorbidities coexist. The pooling of two jurisdic-
tions (as per the funding requirements) for this study
provides useful comparisons across the jurisdictions,
especially as there are differing healthcare systems.
CONCLUSION
The cost of overweight and obesity is substantial, multifa-
ceted and likely to increase. This paper quantiﬁes the
avoidable costs attributable to overweight and obesity
and should motivate policymakers to urgently consider
evidence pertaining to overweight and obesity preven-
tion strategies, and their cost-effectiveness, as part of the
development of a coherent policy response.
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